@moshakes_911 chickpea598 BioBreakout think $ONCS has a plan. wouldhave done an offering if they didnโt have a reason to believe stock will go up. Multiple catalysts coming up - Nov 30 melanoma; Dec 6 TNBC; earnings update before Dec 15; Dec 20 Shareholders meeting; TAVO with Opdivo in melanoma and SCCHN before YE.
PeerView is spending Valentine's Day in Scottsdale with Head and Neck Cancer Alliance, Drs. Ezra Cohen & Andrew Sharabi UC San Diego Health, & Barbara Burtness Yale Cancer Center. Hear what they have to say about multimodal SCCHN care in the #immunotherapy era! #HNCS18 . For more --> peerview.com/HNC
And ISO101b trial with HPV vaccine in HPV+ RMSCCHN now open in Taunton #SCCHN #HPV @mphresearch Chris Levett ๐ณ๏ธโ๐๐ Simon Goldsworthy
PeerView is at #ASCO19 ! They are hosting 8โฃ symposia in two daysโผ๏ธ
โด๏ธTomorrow-May 31st: #RCC , #SCCHN (@hncalliance), #PancreaticCancer (@letswinpc Lustgarten Foundation), #BCell , #Myelofibrosis
โด๏ธSaturday-June 1st: #NSCLC , #HCC , #ProstateCancer
Don't miss it: PeerView.com/Chicago19
โญ๏ธ THANK YOU to Drs. Ezra Cohen, Andrew Sharabi, & Barbara Burtness for excellent talks & discussions of multimodal mgmt of SCCHN in the era of #immunotherapy at #HNCS18 PeerView MasterClass
โญ๏ธย THANK YOU to Head and Neck Cancer Alliance for partnering & bringing the voice of patients to #CME
#IMRT improves survival of #SCCHN patients even in resource limited settings. Paper by Nuradh Joseph Prof Ananya๐ Prasad Abeysinghe Dr.N.Jeyakumaran selected as the #freeaccess #Editorschoice article of Clinical Oncology #radonc #SriLanka SL Cancer Research Group
December's Editor's Choice #freeaccess article: Curative-Intent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck in Sri Lanka: The Impact of Radiotherapy Technique on Survival
Online here clinicaloncologyonline.net/article/S0936-โฆ
The Royal College of Radiologists Clinical Oncology #radiotherapy
Improving access to #IMRT by commissioning more #linacs will improve survival of #SCCHN pts, even in resource limited settings #LMICs .
#Radiotherapy cures #cancer and saves lives but is underfunded and undervalued
#radonc The Sri Lanka College of Oncologists Nuradh Joseph The Royal College of Radiologists ๐งต5/5
Dr. Antonio Calles ๐ซ๐ญ My experience too - in #LCSM and #SCCHN - pseudoprogression not that common but patientโs symptoms are the key Julie Walther Joanne Botten ๐ Lucy Ford Vanessa Fountain The Immunotherapy CNS ๐
The #Duvvurilab is moving to the NYU Grossman School of Medicine !
We are hiring postdocs, students & technicians!
Come study #SCCHN &translate science from!bench to bedside. We study oncogenesis, metabolism & resistance to immunotherapy
From Seahorse ๐scRNA๐CUT&RUN Sarah Hainer Lแปฑc Morris
Good to see this data on the heals of U.S. FDA breakthrough designation of tipifarnib in HRAS mutated #SCCHN ; hope to see an approval for another targeted agent in this disease, ASCO Publications, Alan Ho, @sloan_kettering @HNOPDFCI,Winship Cancer Institute of Emory University, ascopubs.org/doi/10.1200/JCโฆ
Phase III CK651 is out,Despite OS data in the total population, the large benefit seen in the CPS high group is quite notable and durable , again confirming the benefit of IO in first line RM/SCCHN as seen also in K048 Robert Ferris, MD, PhD Glenn J. Hanna, M.D. Kartik Sehgal Dana-Farber News
A few more hours until tonight's PeerView symposia at #ASCO19
๐6:30 PM - Hyatt Regency Chicago (151 East Wacker Drive).๐
A wide range of topics:
โด๏ธ #RCC
โด๏ธ #SCCHN (@hncalliance)
โด๏ธ #PancreaticCancer (@letswinpc Lustgarten Foundation)
โด๏ธ #BCell ,
โด๏ธ #Myelofibrosis
PeerView.com/Chicago19
Today we announced a worldwide licensing agreement with @debiopharmnews for a potentially first-in-class therapy for #headandneckcancer . #SCCHN #cancerresearch
@Lybsoo Innate Pharma Congress Immunology ... that one could be about the SCCHN combo trial cetuximab + monalizumab which did aleady pass phase 2 target of 25% ORR (refer to last #AACR18 poster #CT158 in April: 8 partial responses out of 26 patients in a set of preliminary data); next step would be a registrational study
Compelling data in 1L R/M #SCCHN for Pembro+CTX -- notable oral cavity, PD-L1 low/negative benefit. ๐ง๐๐ฉบEzra Cohen Ravi Uppaluri, MDPhD DanaFarber_HeadNeck
thelancet.com/journals/lanonโฆ
